Today: 21 May 2026
Browse Category

NYSE:MRK 29 December 2025 - 10 January 2026

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Revolution Medicines shares surged 10.7% to $118.64 in after-hours trading Friday after the Financial Times reported Merck is in advanced talks to acquire the company for $28 billion to $32 billion. The move follows the FDA granting Breakthrough Therapy designation to Revolution’s zoldonrasib for KRAS G12D-mutated lung cancer. Investors await Revolution’s Jan. 12 conference appearance for updates.
9 January 2026
··
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck shares rose 1.1% to $108.60 Tuesday, hitting a 52-week high of $110.16 amid investor focus on U.S. vaccine schedule changes and upcoming CEO remarks at the J.P. Morgan Healthcare Conference Jan. 12. The company’s Gardasil HPV vaccine faces uncertainty after the CDC shifted to a single-dose recommendation, while an FDA decision on Keytruda in ovarian cancer is expected Feb. 20.
6 January 2026
··
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck shares edged up a penny to $106.79 in Monday afternoon trading, moving in a tight range on volume of about 4.1 million. The Health Care Select Sector SPDR ETF slipped 0.05% as health-care stocks held steady while major indexes fell. Investors are awaiting Fed minutes and monitoring year-end market signals. Merck’s next earnings report is set for February 3.
29 December 2025
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

Merck shares slipped 0.1% to $106.68 midday Monday, outperforming broader U.S. markets as the S&P 500 ETF fell 0.6% and the Nasdaq-100 tracker dropped 0.7%. Trading volumes remained thin ahead of Federal Reserve minutes due Tuesday. Investors await Merck’s Feb. 3 earnings call for 2026 guidance and pipeline updates. Pending U.S. home sales rose 3.3% in November, beating forecasts.
29 December 2025
··
1 2 3 4 5 6 … 8

Stock Market Today

  • IEA Warns Oil Markets Could Enter 'Red Zone' by July Amid Stock Drawdowns
    May 21, 2026, 8:10 AM EDT. The International Energy Agency (IEA) forecasts oil markets may enter a 'red zone' by July or August due to depleting global stocks and rising demand in the summer travel season. IEA Executive Director Fatih Birol pinpointed the unconditional reopening of the Strait of Hormuz as critical, as this chokepoint handles around 20% of the world's oil and gas shipments. The ongoing Iran conflict and halted shipping there strain supplies, impacting developing Asia and Africa the hardest. Birol noted the recent historic release of 400 million barrels from strategic reserves to offset disruptions, but warned that restoring Middle East production and refining to pre-war levels will take considerable time.

Latest articles

NIO Stock Rises Before Onvo L80 Launch as China EV Demand Faces a Hard Test

Nio slips to red, but margin draws investor attention

21 May 2026
Nio reported first-quarter revenue up 112.2% to RMB25.53 billion ($3.70 billion) and vehicle margin rising to 18.8%. The company posted a net loss of RMB332.1 million, compared to a profit in the previous quarter. Deliveries reached 83,465 vehicles, nearly doubling from a year earlier but down from the fourth quarter. Nio forecast second-quarter revenue and deliveries above analyst expectations.
IBM Stock Tumbles After Earnings Beat as Software Slowdown Reignites AI Fears

IBM, Rigetti, D-Wave gain after $2B quantum investment from Washington

21 May 2026
The Commerce Department will provide $2.013 billion in CHIPS Act incentives to nine quantum computing companies, taking minority, non-controlling equity stakes in each. IBM will receive $1 billion to establish a quantum foundry subsidiary, while GlobalFoundries gets $375 million. Shares of several quantum firms rose sharply in premarket trading following the announcement.
Walmart tops estimates, Wall Street reacts to warning

Walmart tops estimates, Wall Street reacts to warning

21 May 2026
Walmart reported first-quarter net revenue of $177.8 billion, up 7.3%, but shares fell 2% in premarket trading after it forecast weaker-than-expected second-quarter sales and profit. U.S. comparable sales rose 4.1%, and e-commerce jumped 26%. Fuel costs cut operating income by 2.5 percentage points. The company kept its full-year sales and profit outlook unchanged.
Go toTop